Evidence map›Paper›PMID 41473552›Full record

ArticleERJ open research2025

Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study.

Gisli G Einarsson, Laura J Sherrard, Andrew J Lee, Jack Carson, Andrew Marshall, Aya Alkhatib, Vanessa Brown, Deirdre F Gilpin, Gerhild Angyalosi, Michael R Loebinger and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Gisli G EinarssonQueen's University Belfast, Belfast, UK.
Laura J SherrardQueen's University Belfast, Belfast, UK.
Andrew J LeeQueen's University Belfast, Belfast, UK.
Jack CarsonQueen's University Belfast, Belfast, UK.
Andrew MarshallQueen's University Belfast, Belfast, UK.
Aya AlkhatibQueen's University Belfast, Belfast, UK.
Vanessa BrownQueen's University Belfast, Belfast, UK.
Deirdre F GilpinQueen's University Belfast, Belfast, UK.
Gerhild AngyalosiNovartis Pharma AG, Basel, Switzerland.
Michael R LoebingerHost Defence Unit, Royal Brompton Hospital and Harefield NHS Foundation Trust, London, UK.
James D ChalmersScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Francesco BlasiInternal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-2285-9970
Charles S HaworthCambridge Centre for Lung Infection, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Eva PolverinoRespiratory Disease Department, Vall d' Hebron University Hospital - VHIR, Barcelona, Spain.
Harm A W M TiddensDept of Paediatric Pulmonology and Allergology, Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5628-6667
Herman GoossensDept of Clinical Microbiology, University Hospital Antwerp, Antwerp, Belgium.
Felix C RingshausenDept of Respiratory Medicine, Hannover Medical School, and Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.ORCID https://orcid.org/0000-0001-9084-4968
Adam T HillDept of Respiratory Medicine, Royal Infirmary of Edinburgh, and University of Edinburgh, Edinburgh, UK.
J Stuart ElbornQueen's University Belfast, Belfast, UK.
Michael M TunneyQueen's University Belfast, Belfast, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Culture-independent molecular techniques could potentially be used to measure microbiological efficacy in response to antibiotic treatment and improve understanding of the role of the airway microbiota in determining response in patients with chronic respiratory disease. Methods: Using molecular methods, we analysed changes in the sputum microbiota in samples from 107 participants with bronchiectasis recruited to the iBEST-1 study, and defined community endotypes based on response to tobramycin inhalation powder (TIP) treatment. The relationship between microbiota metrics in these endotypes and clinical and inflammatory biomarkers were also determined. Results: There was a significant reduction in Conclusions: qPCR may be a useful, culture-independent microbiological efficacy end-point in clinical trials. Using qPCR, participants with bronchiectasis were stratified into endotpyes which predicted response to antimicrobial treatment, potentially allowing for a more personalised approach to therapy.

Identifiers

PMID41473552
PMCPMC12746121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.